These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24295560)

  • 1. Pharmacogenomics of biological treatment in rheumatoid arthritis.
    Xie X; Zhang D; Chen JW; Tian J; Ling GH; Li F
    Expert Opin Biol Ther; 2014 Feb; 14(2):157-64. PubMed ID: 24295560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.
    Ranganathan P
    Pharmacogenomics; 2005 Jul; 6(5):481-90. PubMed ID: 16013998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.
    Coenen MJ; Toonen EJ; Scheffer H; Radstake TR; Barrera P; Franke B
    Pharmacogenomics; 2007 Jul; 8(7):761-73. PubMed ID: 17638513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.
    Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ
    Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rheumatoid arthritis: current status of therapy].
    El Bahri DM; Meddeb N; Sellami S
    Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of tumor necrosis factor for rheumatoid arthritis.
    Moreland LW
    J Rheumatol Suppl; 1999 May; 57():7-15. PubMed ID: 10328137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
    Taniguchi A; Urano W; Tanaka E; Kamatani N
    Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.
    Garcês S; Antunes M; Benito-Garcia E; da Silva JC; Aarden L; Demengeot J
    Ann Rheum Dis; 2014 Jun; 73(6):1138-43. PubMed ID: 23666932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
    Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
    Ranganathan P
    Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
    Voll RE; Kalden JR
    Ann N Y Acad Sci; 2005 Jun; 1051():799-810. PubMed ID: 16127017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
    Weisman MH
    J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis.
    Krintel SB; Palermo G; Johansen JS; Germer S; Essioux L; Benayed R; Badi L; Ostergaard M; Hetland ML
    Pharmacogenet Genomics; 2012 Aug; 22(8):577-89. PubMed ID: 22569225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
    Zhu H; Deng FY; Mo XB; Qiu YH; Lei SF
    Pharmacogenomics; 2014 Mar; 15(4):551-66. PubMed ID: 24624921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.